The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Abstract
BACKGROUND: Obesity is a widespread disease in both the developed and developing world. Few pharmacological approaches for its treatment exist at this time. OBJECTIVE: This review summarises the currently approved obesity therapies and describes a possible new approach for the treatment and prophylaxis of this disease, based on the inhibition of carbonic anhydrases (CAs, EC 4.2.1.1), enzymes involved in several steps of de novo lipogenesis, both in the mitochondria and the cytosol of cells. METHODS: Topiramate and zonisamide, two antiepileptic drugs showing strong CA inhibitory properties, have been reported as an example of this approach, as clinical data have shown that these compounds induce persistent weight loss in obese patients. CONCLUSIONS: The use of topiramate and zonisamide as lead molecules for the design of CA inhibitors targeting isozymes involved in lipogenesis could represent the beginning of a very promising new approach for the treatment of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity and the Environment: Where Do We Go from Here?
Hill, J. O., Wyatt, H. R., Reed, G. W., & Peters, J. C. (2003) · Science · doi:10.1126/science.1079857 · Cited by 2,180
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041 · cited 1×
“Reversal of the abnormalities associated with obesity is one of the main targets in the current clinical management of this disease [8-10] .”
BackgroundDavidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 2×
“Orlistat [3,21-23] is a semisynthetic derivative of lipostatin that inhibits gastric and pancreatic lipases, two key enzymes required for the hydrolysis of dietary fat in the GI tract [3,21-23] .”
BackgroundEffect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Obici, S., Feng, Z., Arduini, A., Conti, R., & Rossetti, L. (2003) · Nature Medicine · doi:10.1038/nm873 · Cited by 548
A war on obesity, not the obese.
Friedman, J. M. (2003) · Science · doi:10.1126/science.1079856 · Cited by 375
Current and investigational antiobesity agents and obesity therapeutic treatment targets
Bays, H. E. (2004) · Obesity Research · doi:10.1038/oby.2004.151 · Cited by 228 · cited 3×
“Among these, it is important to remember agents that affect the leptin/insulin/central nervous system pathways (such as leptin analogues, leptin transport and/or leptin receptor promoters, ciliary neurotrophic factor [Axokine], neuropeptide Y and agouti-related peptide antagonists, pro-opiomelanocortin and cocaine and…”
Background
Cited by
Supuran, C. T. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.009 · Cited by 616
Self-citationNon-Zinc Mediated Inhibition of Carbonic Anhydrases: Coumarins Are a New Class of Suicide Inhibitors
Maresca, A., Temperini, C., Vu, H., Pham, N. B., Poulsen, S.-A., Scozzafava, A., Quinn, R. J., & Supuran, C. T. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809683v · Cited by 521
Self-citationThe link between stress and feeding behaviour
Maniam, J., & Morris, M. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.017 · Cited by 255
Nonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-Diiodo-L-Thyronine in Rats
de Lange, P., Cioffi, F., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., De Matteis, R., Lionetti, L., Mollica, M. P., Goglia, F., et al. (2011) · Diabetes · doi:10.2337/db11-0207 · Cited by 106
Metadata
- Authors
- Supuran, C. T., Fiore, A. D., & Simone, G. D.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-06
- Volume
- 13
- Issue
- 2
- Pages
- 383-392
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2073322616
- Cited by
- 216
- References
- 12
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. https://app.cochat.ai/papers/10.1517/14728214.13.2.383
- The paper
- Supuran, C. T., Fiore, A. D., & Simone, G. D. (2008). Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.13.2.383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
